Australia's Creso Pharma rises on unit expanding PTSD drug trial

Melodiol Global Health

18/07/2022 04:44

** Shares of Creso Pharma Ltd  CPH.AX  rise as much as 13.6%
to A$0.05, post their best intraday pct gain since May 23
    ** Co says Canadian unit Halucenex Life Sciences will
broaden the scope of its phase II trial of psilocybin on
treatment resistant Post Traumatic Stress Disorder(PTSD)
 urn:newsml:reuters.com:*:nASX96ZYNm 
    ** If approved by the regulator, Halucenex will be able to
collect additional clinical trial data, and study on a broader
spectrum of patients on how psilocybin interacts with other
medications 
    ** CPH stock hits highest level since June 10 
    ** Stock down 46.3% YTD, as of last close 

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))